EAN Programme Committee Member, Prof. Aksel Siva, considers current unmet needs in the treatment of multiple sclerosis and shares his hopes for the future. Part 2 of 2.
View Part 1 here.
Speaker disclosures: Prof. Aksel Siva has received honoraria for giving educational presentations at several national or international congresses or symposia and consultation fees from Novartis, Genzyme Bayer, Merck Serono, Roche, Biogen Idec/Gen Pharma of Turkey and Teva, and received travel and registration coverage for attending several national or international congresses or symposia from Merck Serono, Genzyme, Roche, Biogen Idec/Gen Pharma of Turkey, Novartis and Teva.
Filmed at the 3rd Congress of the European Academy of Neurology (EAN), Amsterdam, June 2017.
